Business
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
ALISO VIEJO, Calif., June 25, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025.
About this update from Glaukos Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/77a6c2194b5db7945e3808ce80809faa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ut2n_y.jxI82RS_vr2VjMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/77a6c2194b5db7945e3808ce80809faa","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/JFOXaYaGD8B0LM.yS3ifKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/77a6c2194b5db7945e3808ce80809faa","width":1200,"height":224}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., June 25, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025.","length":459,"tagName":"p"},{"type":"text","content":""Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we’ve made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye diseases. This milestone would not have been possible without the unrelenting dedication of our teams, the trust of our customers and steadfast support of our partners and shareholders," said Thomas Burns, Glaukos chairman and chief executive officer. "Over the past decade, Glaukos has grown from a single-product, U.S.-focused company into a diversified, global leader in ophthalmology, now with more than 1,000 employees around the world. Just as it did at the time of our IPO, innovation remains at the core of everything we do. I am deeply grateful for how far we’ve come, and excited as we embark upon our next transformational decade ahead."","length":952,"tagName":"p"},{"type":"text","content":"Coverage of the NYSE Closing Bell will be live streamed and on replay on the NYSE website at https://ww...